JD Sports Fashion prohibited to acquire Footasylum by CMA

JD Sports

JD Sports Fashion Plc (LON:JD) has noted the announcement earlier today from the Competition and Markets Authority that it has again prohibited JD’s acquisition of Footasylum Limited.

However, the CMA agrees with JD on a number of critical aspects:

·      JD’s most important competitors are now the Direct to Consumer (“DTC”) operations of the international brands themselves rather than Footasylum with a market share of less than 5%.

·      As a result of this merger, there would be no substantial lessening of competition for JD and so, consequently, JD has no incentive to raise prices or worsen its consumer offer.

This is the first time ever that the CMA (including its predecessors) has decided to block or remedy a deal between competitors where it found that there will be no “substantial lessening of competition” in relation to the acquiring business.  

Prior to this, in every other case under the UK merger regime between competitors, including its first review of this merger with Footasylum, the CMA has justified its intervention on the basis that the merger eliminated important rivalry for both the acquiring and the target business.

Given the critical areas in which the CMA agrees with JD and the fundamental change in its conclusion between the two inquiries, the decision to prohibit the acquisition defies logic.

Background to the Second Inquiry

After the Competition Appeal Tribunal ruling that the CMA’s original inquiry had made irrational errors, the CMA was instructed to go back and reconsider the impact of the COVID-19 pandemic.  A key issue was to examine the degree to which the structural “digital shift” to online shopping during the pandemic has fundamentally increased competition from Nike’s and adidas’ own DTC retail offers on JD and Footasylum. At the same time, both parties rely on these competitors, Nike and adidas, for access to and supply of a significant number of key products.

JD Sports Fashion agrees with the CMA’s revised conclusions in relation to some of the impacts of the pandemic:

·      Overall, the CMA concluded that “market developments … have resulted in Footasylum becoming a weaker constraint and other competitors becoming stronger“.

·      The CMA also found that Footasylum’s market share is less than 5% and it no longer considers Footasylum to be the “strong” competitor to JD that it was pre-pandemic. 

·      In comparing between the two surveys that it commissioned in its inquiries either side of the pandemic, the CMA found that “More JD Sports customers now consider Nike, Foot Locker and adidas as their alternatives than they do Footasylum“.

As a result, it is inexplicable to JD that the CMA remains of the view that one small competitor, Footasylum, with less than 5% of the market, is not subject to the same competitive pressures and discipline from Nike and adidas DTC that affects the remaining 95%+ of the market.   

Implications

The practical result of this extreme and unprecedented finding is that the CMA requires the unwinding of the acquisition, which closed in May 2019, meaning that JD cannot invest in and improve Footasylum’s customer proposition, as it has always intended to do.

JD is studying the report in detail and will carefully consider its options accordingly.

Peter Cowgill, Executive Chairman of JD Sports Fashion Plc, commented:

“The CMA rightly concludes that, following the acquisition of Footasylum, JD would have no incentive to raise prices or worsen its offer as its most important competitors are the DTC operations of the international brands themselves.

“However, the CMA has then somehow concluded that the competitive threat from DTC does not extend to Footasylum and that JD would have an incentive to worsen the offer in Footasylum to the detriment of both consumers and suppliers. We would suggest that the CMA is in a minority of one in reaching this conclusion.

“Overall, the CMA’s decision today continues to be inexplicable to anyone who understands what difference the pandemic has made to UK retail and how competition and the supply chain in our markets actually work. It is deeply troubling at a time when the UK high street has been seriously damaged already and is vulnerable to further closures.”

Share on:
Find more news, interviews, share price & company profile here for:

    Global Opportunities Trust reports 11.9% one year share price return to 31 August

    Global Opportunities Trust has released its August 2025 factsheet, reporting a 12-month NAV increase of 8.8% and a share price gain of 11.8%.

    Dekel Agri-Vision reports 24.5% revenue growth and break-even net profit in H1 2025

    Dekel Agri-Vision posted a stronger performance for the six months ended 30 June 2025, with Group revenue up 24.5% to €23.9m and EBITDA rising 10.7% to €3.1m.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Quadrise signs addendum with Valkor to re-phase payments and MMU deliveries

    Quadrise has agreed an addendum to its Site License and Supply Agreement with Valkor Technologies in Utah. The revised terms re-phase the US$1.0 million licence fee through to June 2026 and adjust delivery schedules for Multifuel Manufacturing Units.

    Ampeak Energy reports interim results and financial close of first battery project

    Ampeak Energy has published its unaudited interim results for the six months ended 30 June 2025. The Group focused on achieving financial close of the 240 MWh AW1 battery project at Uskmouth, which was completed in August 2025.

    Nuformix to present NXP002 data at ERS Congress 2025

    Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis.

      Search

      Search